Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0036572 (seizures)
 80,221 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

1. The effects of the octapeptide angiotensin II (AT II) on some types of behaviour [threshold of seizures induced by timed intravenous infusion of pentylenetetrazol (PTZ), exploratory behaviour: ambulation, rearing and head-dips on a hole-board, and passive avoidance performance--step-through paradigm] were studied following repeated systemic administration of MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) to mice (30 mg/kg, i.p., twice daily for 5 days). AT II was administered s.c. (200 micrograms/kg), single and repeated (for 7 days) 7 days after withdrawal of MPTP. 2. PTZ seizure threshold was significantly increased by AT II both in groups with single and repeated administration (stronger than in the group treated only with MPTP and in the group untreated with MPTP). 3. AT II significantly increased the ambulation and rearing as well as the head-dips both on single and repeated administration as compared to groups treated and untreated with MPTP. 4. Administered immediately after the passive training trial AT II, on single and repeated administration, significantly increased latencies, i.e. it facilitated retention, in MPTP-treated mice. 5. These results were discussed in the light of DA and perhaps, GABA receptor supersensitivity developed in susceptible brain structures after withdrawal of repeated MPTP administration. 6. The adaptive changes in the effects of AT II on seizure threshold, exploratory behaviour and retention of passive avoidance performance might be associated with the altered receptor-receptor (AT II-DA-GABA) interactions in the brain.
Gen Pharmacol 1991
PMID:Behavioural effects of angiotensin II in the mouse following MPTP administration. 165 86

The rate at which SJL/J mice recover susceptibility following an initial sound-induced seizure was examined. Fewer than 15% of the subjects seized when retested after a 2-min delay, and only 50% reseized after a 10-min delay. The likelihood of a second seizure was enhanced if the initial seizure exhibited a rapid progression to clonus. During the retest, seizures progressed more slowly than during the initial test, which indicates that recovery was not complete even if a second seizure was induced. Finally, recovery of seizure susceptibility was prevented as long as the subject continued to be exposed to intense auditory stimulation following the initial convulsion, an effect previously noted by Alexander and Kopeloff (1980). The findings are discussed in terms of a recently proposed central inhibitory model of the recovery of audiogenic seizure susceptibility.
J Gen Psychol 1991 Jul
PMID:Recovery of susceptibility following audiogenic seizure in mice. 175 83

Rats were exposed for 24 min to bilateral clamping of the common carotid arteries (BCCA) in pentobarbital anaesthesia. 14 days later the animals were subjected to subcutaneous injection of (+)-bicuculline (3 or 4 mg/kg). A significantly decreased susceptibility to bicuculline-induced seizures could be observed in BCCA treated rats compared with sham operated controls. It is suggested that BCCA treatment protects animals against status epilepticus and lethal toxicity produced by bicuculline. Electrographic recordings of the BCCA animals revealed no ictal activity within 1 h after bicuculline injection. An analysis of the GABA content showed a significant increase in the hippocampus (HPC), frontal cortex (FCX), parietal cortex and substantia nigra in BCCA animals compared with controls. It is therefore possible that an increase in GABA content postsynaptically counteracts the GABAA antagonistic effect of bicuculline in BCCA animals thus preventing the normal seizure inducing effect of this substance.
J Neural Transm Gen Sect 1991
PMID:Decreased susceptibility to seizures induced by bicuculline after transient bilateral clamping of the carotid arteries in rats. 185 Feb 83

Bromocriptine, an ergot alkaloid dopamine agonist, is a recent common treatment for suppression of lactation in postpartum women. A case is presented of a postpartum woman prescribed bromocriptine for suppression of lactation who developed hypertension, headaches, blurry vision, seizures, and pituitary hemorrhage. Differential diagnosis and a literature review are considered.
Gen Hosp Psychiatry 1991 Jul
PMID:Bromocriptine associated with postpartum hypertension, seizures, and pituitary hemorrhage. 187 30

Two double-blind studies at 21 centers evaluated the therapeutic efficacy, safety, and tolerability of up to 300 mg/d of clomipramine hydrochloride or an equivalent number of placebo capsules in the treatment of 520 patients with obsessive-compulsive disorder, of whom 239 had had the disorder for at least 2 years (study 1) and 281 had been ill for at least 1 year (study 2). On the two principal measures of the severity of the disorder, ie, the Yale-Brown Obsessive Compulsive Scale and the National Institute of Mental Health Global Obsessive Compulsive Scale, clomipramine was significantly more effective than placebo in both studies. The mean reduction in the Yale-Brown Obsessive Compulsive Scale score at the end of 10 weeks of treatment was 38% and 44% in studies 1 and 2, respectively, for the clomipramine-treated patients and 3% and 5% for the placebo-treated patients. The drug was also found to be superior on the basis of the physicians' and patients' evaluations of global therapeutic change. The most frequently observed adverse effects during clomipramine therapy were those typically associated with tricyclic antidepressant drugs. Although uncommon, the occurrence of seizures and elevated aminotransferase values are potentially serious side effects of clomipramine. Clomipramine was generally well tolerated and was effective in reducing obsessive and compulsive symptoms.
Arch Gen Psychiatry 1991 Aug
PMID:Clomipramine in the treatment of patients with obsessive-compulsive disorder. The Clomipramine Collaborative Study Group. 188 60

In a random-assignment, double-blind, controlled comparison in 38 melancholic men, overall antidepressant potency of high-dose electroconvulsive therapy (378-mC charge) given with right unilateral electrode placement was not significantly different from that with bilateral placement, although there was a trend for faster improvement with bilateral ECT. The suprathreshold character of the stimulus, about 2.5 times the expected seizure threshold, may have contributed to the high efficacy of brief-pulse right unilateral electroconvulsive therapy found in this study.
Arch Gen Psychiatry 1991 Aug
PMID:Antidepressant effects of high-dose right unilateral electroconvulsive therapy. 188 58

Electroconvulsive therapy is accompanied by an activation of the hypothalamic-pituitary-adrenal axis, resulting in a release of beta-endorphin from the anterior pituitary corticotrophs of humans. As a group, patients in our study demonstrated similar plasma beta-endorphin immunoreactivity response to their initial and final treatments. However, approximately half of the patients demonstrated greater beta-endorphin immunoreactivity release with their first seizure compared with their last seizure, and half of the patients demonstrated the opposite pattern. This difference was not explained by age, sex, unilateral vs bilateral treatments, sine wave vs brief pulse, or psychotropic or anticholinergic medication. Patients with constant seizure duration during the first and final treatments demonstrated a greater release of beta-endorphin immunoreactivity with the final treatment compared with the first treatment. Individuals with decreasing seizure duration during the course of the electroconvulsive therapy demonstrated a decreased beta-endorphin immunoreactivity response during their final treatment.
Arch Gen Psychiatry 1991 Jun
PMID:Heterogeneity in the beta-endorphin immunoreactivity response to electroconvulsive therapy. 203 37

To evaluate the feasibility of cingulotomy as a treatment for patients with intractable obsessive-compulsive disorder, we evaluated the records of all 35 patients with this diagnosis who had undergone one or more such procedures at Massachusetts General Hospital, Boston, during the last 25 years. Retrospectively, all but two of these patients met DSM-III-R criteria for obsessive-compulsive disorder. Six patients were deceased; four by suicide. Questionnaires were sent to the remaining 27 patients with obsessive-compulsive disorder; 17 patients returned the questionnaire and another agreed to an interview without completing the forms. Sixteen of these 18 patients participated in a telephone interview, and patient reports were corroborated by an informant in 10 cases. Despite the presence of some side effects, such as easily controlled seizures (9%) and transient mania (6%), the results of this investigation support the use of cingulotomy as a potentially effective treatment for patients with severe and disabling obsessive-compulsive disorder. With the use of very conservative criteria, we estimated that at least 25% to 30% of the patients benefited substantially from this procedure. Similar results were found in a preliminary prospective study of four patients who recently underwent cingulotomy after state-of-the-art preoperative treatments had failed.
Arch Gen Psychiatry 1991 Jun
PMID:Cingulotomy for refractory obsessive-compulsive disorder. A long-term follow-up of 33 patients. 162 52

An interdisciplinary team discussed the case of a 31-year-old woman who sustained second- and third-degree burns while having a seizure. She was a difficult patient who elicited a good deal of negative feelings from the staff. The interview raised the possibility of this burn having been a suicidal attempt, and the subsequent discussion centered on effective ways of relating to her pathologic defense mechanisms. The need for a comprehensive approach that took into consideration the biologic, psychologic, and social aspects of her needs became evident to all the participants.
Gen Hosp Psychiatry 1990 May
PMID:A "hateful epileptic" patient in the burn unit. 211 May 43

L-phenylisopropyladenosine (L-PIA; a preferential A1 adenosine agonist-0.05 mg/kg) offered no protection against electroconvulsions in mice but potentiated the anticonvulsant action of diazepam and valproate against maximal electroshock-induced seizures, decreasing the respective ED50 values from 9.5 to 4.0 mg/kg and from 250 to 185 mg/kg. However, it remained without effect on the protective activity of phenobarbital, carbamazepine and diphenylhydantoin. 5'-N-ethylcarboxamidoadenosine (NECA; a preferential A2 adenosine agonist-0.5 mg/kg) potentiated the efficacy of valproate. On the other hand, NECA (1 mg/kg) diminished the anticonvulsant action of phenobarbital (ED50 was elevated from 16.5 to 20.5 mg/kg), possessing no effect upon the protective action of carbamazepine. In addition, papaverine (20 mg/kg) significantly enhanced the protective efficacy of valproate and up to 40 mg/kg remained without influence upon the protective action of carbamazepine. However, papaverine (20 and 40 mg/kg) inhibited the anticonvulsive potential of phenobarbital. In the light of the results obtained A1 and A2 adenosine receptor-mediated events seem to possess different influences upon the protective effects of antiepileptic drugs.
J Neural Transm Gen Sect 1990
PMID:Differential effects of agents enhancing purinergic transmission upon the antielectroshock efficacy of carbamazepine, diphenylhydantoin, diazepam, phenobarbital, and valproate in mice. 211 25


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>